Supernus Pharmaceuticals, Inc. (SUPN) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 9 Buy, 5 Hold.
The consensus price target is $61.67 (low: $55.00, high: $65.00), representing an upside of 23.1% from the current price $50.11.
Analysts estimate Earnings Per Share (EPS) of $2.87 and revenue of $0.64B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $1.34 vs est $2.87 (missed -53.4%). 2025: actual $-0.68 vs est $3.10 (missed -122%). Analyst accuracy: 0%.
SUPN Stock — 12-Month Price Forecast
$61.67
▲ +23.07% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Supernus Pharmaceuticals, Inc., the average price target is $61.67, with a high forecast of $65.00, and a low forecast of $55.00.
The average price target represents a +23.07% change from the last price of $50.11.
Highest Price Target
$65.00
Average Price Target
$61.67
Lowest Price Target
$55.00
SUPN Analyst Ratings
Buy
Based on 14 analysts giving stock ratings to Supernus Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — SUPN
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $1.34
vs Est $2.87
▼ 114.4% off
2025
Actual –$0.68
vs Est $3.10
▼ 555.5% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect the company to turn profitable.
Revenue Estimates — SUPN
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.662B
vs Est $0.643B
▲ 2.9% off
2025
Actual $0.719B
vs Est $0.703B
▲ 2.3% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
